Compare Trump Media and Technology Group Corp (DJT) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trump Media and Technology Group Corp vs Mesoblast Limited — how do they compare? Trump Media and Technology Group Corp trades at $8.11 (market cap $2.28B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Trump Media and Technology Group Corp is the larger of the two by market cap, and Mesoblast Limited is more actively traded (239,027 versus 3,148,379). Which is the better fit depends on your goals — on Pluang, investors hold Trump Media and Technology Group Corp for 17 Days and Mesoblast Limited for 15 Days on average.
| DJT | MESO | |
|---|---|---|
Market Cap | $2.28B | $1.75B |
Volume | 3,148,379 | 239,027 |
Sector | Media | Health |
52-Week High | $16.56 | $20.96 |
52-Week Low | $7.06 | $13.19 |
Typical Hold Time | 17 Days | 15 Days |
Enterprise Value | $2.35B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DJT trades at $8.20, down 0.24% with a bearish technical signal. The company reported $3.68M revenue for 2025 but a net loss of $712M, reflecting negative margins. Cash flow trends show heavy investing outflows partially funded by financing. Recent news highlights a proposed merger with TAE Technologies and insider selling activity.
Outlook remains challenged by persistent losses and high valuation multiples. The merger with TAE offers strategic diversification but execution risk is high. Investor sentiment is cautious amid weak fundamentals and negative profitability trends.
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Trump Media and Technology Group Corp
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
